Skip to content
Medical Health Aged Care

Psilocybin has treatment potential for a range of psychiatric conditions but remains poorly understood

The Florey 2 mins read
Florey Researcher, James Gattuso

Medicinal psilocybin may prove to be an untapped therapeutic resource for a variety of psychiatric conditions identified by researchers at The Florey. 

In a paper published in the Journal of Neurochemistry, Florey researchers found that despite a recent “research explosion” into the naturally occurring psychoactive substance found in magic mushrooms, how it works remains poorly understood and needs to be subject of rigorous scientific research. 

Lead author James Gattuso said the team, led by Dr Thibault Renoir at The Florey, systematically reviewed 34 preclinical scientific papers published since 2000 to help shape the future direction of psilocybin research. 

"Psilocybin shows the greatest efficacy for mood disorders such as depression and anxiety. It also shows exciting therapeutic potential for obsessive compulsive disorder, addiction, and fear-related disorders such as post-traumatic stress disorder and phobias,” Mr Gattuso said. 

"Psilocybin has been found to be as safe if not safer than ketamine, which is FDA-approved for treatment-resistant depression. However, when taken recreationally, psilocybin is not only illegal but can carry significant health risks and concerns particularly for people with existing mental health conditions.” 

Mr Gattuso said future research should explore safe and long-term effects of psilocybin treatment. 

The review identified a variety of important future research directions, noting researchers could consider: 

  • Investigating how psilocybin affects the gut-brain axis which enables two-way biochemical signalling to take place between the gastrointestinal tract and the central nervous system and is known to be relevant to several neuropsychiatric conditions. 

  • Studying whether any benefits are due to psilocybin’s hallucinogenic properties or to other physiological factors. 

  • Working with genetically-engineered animal models as these allow researchers to understand the complex interaction between genes and environment and their impacts on behaviour. 

“We focused on preclinical psilocybin research because such studies can tightly control behavioural experiments, are less impacted by placebo effects and enable biochemical processes to be understood” Mr Gattuso said. 

The researchers also found that psilocybin can robustly increase the strength of synaptic connections while also altering the way key brain networks ‘talk’ to each other.  

Psilocybin was reclassified by the Therapeutic Goods Administration in Australia in July this year to allow prescription for patients with treatment-resistant depression, while the American Food and Drug Administration has classified it as a “breakthrough therapy”.  

The researchers concur that a limitation of the field is that the studies that were systematically reviewed contained large variability in study design such as the disease model, dosages used and behavioural tests applied. Therefore, much more research is needed to identify new treatments, including psilocybin and related drugs, for a variety of major psychiatric disorders. 

Read more about psilocybin research now underway at The Florey 


Contact details:

Media contact

Kath Powley, Manager, Media and Communications
kathryn.powley@florey.edu.au | +61 456 666 271

Media

More from this category

  • Disability, Medical Health Aged Care
  • 24/05/2024
  • 07:28
Developing Australian Communities

MEDIA CALL 9:30AM Minister Kate Washington Opening NSW Largest Disability and NDIS Event – ICC Sydney Hall 6, Level 4

IMMEDIATE MORNING MEDIA CALL TODAY 9:30AM - ICC Sydney Hall 6 Inside Hall 930am - Minster Kate Washington Official Opening to Camera at Stage to Crowd of Providers - Media Opportunity, Inside Hall 6 at Centre Stage, Level 4 9:55am Door stop Ribbon Pull Opening - Short Opening to Camera at Door of Hall 6, Level 4 Minister Kate Washington Developing Australian Communities Co-founders Mr River Night and Mr Mike Clark ICC Sydney CEO Geoff Donaghy Event name: Sydney Disability Connection Expo, sponsored by Easy Healthcare Event Details and Link https://developingauscommunities.com.au/sydney-expo-2024-visitor/ Venue Link for Address and details https://iccsydney.com.au/ Minister WILL…

  • Medical Health Aged Care
  • 24/05/2024
  • 05:00
Palliative Care Australia

Distressing lack of access to palliative care highlighted in new data

New data released during National Palliative Care Week reveals the benefits of palliative care for those with a terminal diagnosis but also highlights a…

  • Contains:
  • Medical Health Aged Care
  • 23/05/2024
  • 15:10
Dementia Australia

ONE WEEK TO GO until the Gold Coast Memory Walk & Jog!

With only a few sleeps to go walkers, joggers and runners are gearing up to participate in the 2024 Gold Coast Memory Walk & Jog. More than 560 people have already signed-up to take part – but there’s always room for more with online registrations still open, or sign-up on the day of the event. Dementia Australia Executive Director Services, Advocacy & Research Dr Kaele Stokes, said it is fantastic to see Gold Coast locals throwing their support behind Memory Walk & Jog. “As we prepare to host Memory Walk & Jog on Sunday 2 June at Pratten Park, Broadbeach…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.